title: Access to advanced therapy medicinal products in the EU: where do we stand?
abstract: The European Union has a public health strategy and will generally ensure in all its policies and activities a "high level of human health protection". The new Regulation (EC) n 1394/2007 on advanced therapy medicinal products (ATMP), stems from this global policy and aims to harmonise access to the ATMP market. A real will for the harmonisation is clearly expressed in legal texts and enforced in the implementable procedures and requirements. However, several barriers remain. On the one hand, the scope of the ATMP Regulation is limited. On the other hand, Member States benefit from a wide margin of action.
authors.affiliation: INSERM UMRS 1027, Université de Toulouse, Université Paul Sabatier - Toulouse III, France. mahalat@cict.fr
authors.forename: A
authors.initials: A
authors.lastname: Mahalatchimy
mesh_terms: D017690:Cell Transplantation / Q000331:legislation & jurisprudence*; D005062:European Union; D015316:Genetic Therapy / Q000331:legislation & jurisprudence*; D006291:Health Policy; D006297:Health Services Accessibility / Q000331:legislation & jurisprudence*; D006801:Humans; D009313:National Health Programs / Q000331:legislation & jurisprudence*; D023822:Tissue Engineering / Q000331:legislation & jurisprudence*